{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:38:27Z","timestamp":1790314707027,"version":"4.1.0"},"reference-count":64,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The standard of care in severe haemophilia A is prophylaxis, which has historically aimed for a factor VIII (FVIII) trough level of \u22651%. However, despite prophylactic treatment, people with haemophilia remain at risk of bleeds that have physical and quality of life implications, and that impact everyday life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this review was to evaluate evidence supporting the relationship between targeting higher FVIII activity levels with prophylaxis and improved outcomes in people with haemophilia A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a narrative review that defined the unmet needs and treatment goals in people with haemophilia A, evaluated evidence to support targeting higher FVIII activity levels, and highlighted therapies that may support higher and sustained FVIII activity levels and improved outcomes for people with haemophilia A.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Despite recent advances in treatment, unmet needs remain, and people with haemophilia continue to experience joint and functional impairment, acute and chronic pain, and poor mental health. All these negatively impact their health\u2010related quality of life. Evidence suggests that FVIII activity levels of up to 50% may be needed to achieve a near\u2010zero joint bleed rate. However, achieving high FVIII activity levels with current standard and extended half\u2010life (EHL) FVIII replacement therapies is associated with a high treatment burden. Innovative treatment options may provide high sustained FVIII activity levels and improved patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evidence suggests that FVIII activity levels in people with haemophilia A should be sustained at higher levels to improve joint and patient outcomes and enable progression towards health equity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.14866","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:03:38Z","timestamp":1695852218000},"page":"1419-1429","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review"],"prefix":"10.1111","volume":"29","author":[{"given":"Lynn","family":"Malec","sequence":"first","affiliation":[{"name":"Versiti Blood Research Institute  Milwaukee Wisconsin USA"},{"name":"Division of Hematology &amp; Oncology Departments of Medicine and Pediatrics Medical College of Wisconsin  Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Matino","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Thromboembolism Department of Medicine McMaster University  Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"issue":"8","key":"e_1_2_15_3_1","article-title":"Clotting factor concentrates for preventing bleeding and bleeding\u2010related complications in previously treated individuals with haemophilia A or B","volume":"8","author":"Olasupo OO","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03270.x"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13215"},{"key":"e_1_2_15_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13985"},{"key":"e_1_2_15_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13862"},{"key":"e_1_2_15_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12567"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S139851"},{"key":"e_1_2_15_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13449"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01798-4"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01750.x"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001311"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14171"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13811"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24133"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12637"},{"key":"e_1_2_15_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12107"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2021.03.157"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.5482\/HAMO-14-03-0021"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14571"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13027"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S212723"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24220"},{"key":"e_1_2_15_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.07.015"},{"key":"e_1_2_15_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14487"},{"key":"e_1_2_15_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13917"},{"key":"e_1_2_15_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02383.x"},{"key":"e_1_2_15_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020552"},{"key":"e_1_2_15_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852"},{"key":"e_1_2_15_32_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1709519"},{"key":"e_1_2_15_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.241554"},{"key":"e_1_2_15_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12905"},{"key":"e_1_2_15_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.12727"},{"key":"e_1_2_15_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005673"},{"key":"e_1_2_15_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12175"},{"key":"e_1_2_15_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12195"},{"key":"e_1_2_15_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01575"},{"key":"e_1_2_15_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12920"},{"key":"e_1_2_15_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14363"},{"key":"e_1_2_15_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009217"},{"key":"e_1_2_15_43_1","unstructured":"GenentechI Hemlibra Prescribing Information.2022. Accessed November 3 2022.https:\/\/www.gene.com\/download\/pdf\/hemlibra_prescribing.pdf"},{"key":"e_1_2_15_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000849"},{"key":"e_1_2_15_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004334"},{"key":"e_1_2_15_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010331"},{"issue":"1","key":"e_1_2_15_47_1","article-title":"New factor VIII function\u2010mimetic bispecific antibodies engineered from emicizumab for further improving the treatment of Hemophilia A [abstract]","volume":"4","author":"Teranishi Y","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_15_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15270"},{"key":"e_1_2_15_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00037-6"},{"key":"e_1_2_15_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00284-2"},{"key":"e_1_2_15_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006403"},{"key":"e_1_2_15_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14207"},{"key":"e_1_2_15_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12438"},{"key":"e_1_2_15_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166522"},{"key":"e_1_2_15_55_1","unstructured":"ChowdaryP AngchaisuksiriP ApteS et\u00a0al.Concizumab prophylaxis in patients with haemophilia A or B without inhibitors: efficacy and safety results from the primary analysis of the phase 3 explorer8 study.2023."},{"key":"e_1_2_15_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18495"},{"key":"e_1_2_15_57_1","doi-asserted-by":"crossref","unstructured":"KaddiC TaoM LeiserR et\u00a0al. Development of a quantitative systems pharmacology model to explore hemostatic equivalency of antithrombin lowering [abstract].2022.","DOI":"10.1182\/blood-2022-169043"},{"key":"e_1_2_15_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-713289"},{"key":"e_1_2_15_59_1","doi-asserted-by":"publisher","DOI":"10.17225\/jhp00158"},{"key":"e_1_2_15_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209226"},{"key":"e_1_2_15_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001292"},{"key":"e_1_2_15_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002699"},{"key":"e_1_2_15_63_1","unstructured":"IncBT ALTUVIIIO Prescribing Information.2023. Accessed February 24 2023https:\/\/www.fda.gov\/media\/165594\/download"},{"key":"e_1_2_15_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211075"},{"key":"e_1_2_15_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113708"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T06:19:58Z","timestamp":1705645198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1111\/hae.14866"],"URL":"https:\/\/doi.org\/10.1111\/hae.14866","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"2023-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}